Clin2
NCT04220190Possibly a fitRecruiting

Study drug made from your immune cells for ALS

Amyotrophic Lateral Sclerosis

Part of Brain & nervous system, Hormones & metabolism clinical trials.

This trial tests RAPA-501, a treatment made using your own immune cells, to slow progression of ALS. It may help by changing how your immune system responds in ALS.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
41 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You’re an adult (age 18 or older), and you have ALS (sporadic or inherited).
  • Your ALS symptoms started within the last 24 months.
  • Your ALS function score (ALSFRS-R) is between 34 and 45.
  • You must have enough immune cells for the treatment: CD3+ T-cells at least 500 cells per microliter from a blood test.
  • You can still be on ALS medicines like riluzole, edaravone, or Relyvrio if your dose stayed the same for at least 30 days.
  • Your breathing and blood tests must meet limits (breathing “slow vital capacity” at least 70%, and kidney/liver and bilirubin within set ranges).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06315608Not yet recruiting· Phase 2
Testing MRG-001 for people with ALS

This trial tests an experimental drug called MRG-001 for people with amyotrophic lateral sclerosis (ALS). It aims to see if the drug can help slow the progression of the disease.

NCT06513546Not yet recruiting· Phase 1/Phase 2
Testing a new drug (PLL001) for early-stage ALS

This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and if it can slow the progression of the disease. You may be a good fit if you have been recently diagnosed and are still in the early stages of ALS.

NCT07660614Recruiting· Phase 1/Phase 2
Testing a new drug for people with ALS

This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.

Lübeck
NCT06726577Recruiting· Phase 1/Phase 2
A new drug for ALS: phase 1/2 safety and effectiveness trial

This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.

Suzhou, Jiangsu
NCT02478450Not yet recruiting· Phase 1/Phase 2
Testing Q-Cells for ALS

This study tests a new treatment called Q-Cells®, which are special cells injected into the spinal cord to see if they can help slow ALS. It is for people with ALS who have a caregiver and are healthy enough to undergo the procedure.

NCT06126315Recruiting· Phase 2/Phase 3
Testing acetyl-L-carnitine in early ALS

This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.

Sydney

Hear when a new Amyotrophic Lateral Sclerosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.